IDDF2019-ABS-0318 Identification of gut microbiota and metabolites signature in patients with irritable bowel syndrome

Abstract

Background Irritable bowel syndrome (IBS) is the most common gastrointestinal disorder with a prevalence of 10%∼15%. The underlying mechanism of IBS is largely unknown. This study aimed to determine whether fecal metabolite and microbiota profiles could act as biomarkers for IBS and to uncover the possible gut microbe-metabolite associations. Methods By using a gas chromatography coupled to time-of-flight mass spectrometer (GC-TOFMS) and 16S rDNA amplicon sequencing, fecal metabolites and microbiota of 15 healthy volunteers (normal control =NC) and 15 adult IBS patients were measured. Results The IBS patients had a significantly differential metabolite profile as compared to NC group, 4 clusters with 31 metabolites were significantly up-regulated in the IBS group as compared to the NC group. Compared with the NC group, 19 microbes were significantly up-regulated and 12 microbes were down-regulated in the IBS group. The correlation matrices between IBS clinical traits and differential abundant metabolites (DAMts) or microbes (DAMbs) indicated that partial DAMts clusters were positively associated with age, the frequency of abdominal pain/abdominal discomfort and the number of bowel movements; part of DAMbs clusters was also positively associated with those above-mentioned symptoms. By correlating metabolite levels with the amount of microbial genera, a network and correlation matric was generated to identify two DAMts/DAMbs core panels for IBS and NC groups. Conclusions The finding of this study puts a global perspective on metabolomics and microbiota profiling in IBS patients and provides a theoretical basis for future research on the pathophysiology of IBS.